AGEN Agenus Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AGEN

Price (delayed)

$6.56

Market cap

$137.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.64

Enterprise value

$163.04M

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the ...

Highlights
The gross profit has soared by 94% YoY and by 4.8% from the previous quarter
Agenus's revenue has soared by 70% YoY and by 3.3% from the previous quarter
The quick ratio has plunged by 79% YoY and by 48% from the previous quarter
AGEN's equity is down by 26% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.agenusbio.com
Peers: NWBO MRK JNJ CLDX

Key stats

What are the main financial stats of AGEN
Market
Shares outstanding
21M
Market cap
$137.76M
Enterprise value
$163.04M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.01
Earnings
Revenue
$161.42M
EBIT
-$128.59M
EBITDA
-$114.19M
Free cash flow
-$208.65M
Per share
EPS
-$12.64
Free cash flow per share
-$10.24
Book value per share
-$9.62
Revenue per share
$7.92
TBVPS
$11.18
Balance sheet
Total assets
$256.56M
Total liabilities
$446.88M
Debt
$78.14M
Equity
-$201.43M
Working capital
-$195.65M
Liquidity
Debt to equity
-0.39
Current ratio
0.24
Quick ratio
0.21
Net debt/EBITDA
-0.22
Margins
EBITDA margin
-70.7%
Gross margin
99.4%
Net margin
-148.3%
Operating margin
-85.6%
Efficiency
Return on assets
-74.3%
Return on equity
N/A
Return on invested capital
-267.6%
Return on capital employed
-23,086.9%
Return on sales
-79.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGEN stock price

How has the Agenus stock price performed over time
Intraday
10.07%
1 week
9.52%
1 month
-53.84%
1 year
-78.13%
YTD
-60.38%
QTD
-60.84%

Financial performance

How have Agenus's revenue and profit performed over time
Revenue
$161.42M
Gross profit
$160.49M
Operating income
-$138.24M
Net income
-$239.39M
Gross margin
99.4%
Net margin
-148.3%
The gross profit has soared by 94% YoY and by 4.8% from the previous quarter
Agenus's revenue has soared by 70% YoY and by 3.3% from the previous quarter
AGEN's operating margin has soared by 59% YoY and by 16% from the previous quarter
Agenus's net margin has increased by 41% YoY and by 6% QoQ

Growth

What is Agenus's growth rate over time

Valuation

What is Agenus stock price valuation
P/E
N/A
P/B
N/A
P/S
0.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.01
The EPS is up by 23% year-on-year and by 8% since the previous quarter
AGEN's equity is down by 26% QoQ
The stock's price to sales (P/S) is 86% less than its 5-year quarterly average of 5.2 and 77% less than its last 4 quarters average of 3.3
Agenus's revenue has soared by 70% YoY and by 3.3% from the previous quarter

Efficiency

How efficient is Agenus business performance
The return on sales has surged by 57% year-on-year and by 16% since the previous quarter
Agenus's ROIC has plunged by 55% YoY and by 36% from the previous quarter
Agenus's return on assets has decreased by 32% YoY and by 9% QoQ

Dividends

What is AGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGEN.

Financial health

How did Agenus financials performed over time
AGEN's total assets is 43% lower than its total liabilities
The quick ratio has plunged by 79% YoY and by 48% from the previous quarter
Agenus's current ratio has shrunk by 78% YoY and by 45% QoQ
Agenus's debt is 139% higher than its equity
The debt to equity has surged by 71% year-on-year and by 20% since the previous quarter
AGEN's equity is down by 26% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.